Conexiant’s news site is now MDSpire News. Learn more
Advertisement
DOOR framework shows similar outcomes in skin infection trials
“Using DOOR can provide clinicians and patients with a better understanding of the benefits and risks of new anti-infectives being studied to treat skin infections.”
Clinical Scorecard: DOOR framework shows similar outcomes in skin infection trials
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: DOOR framework shows similar outcomes in skin infection trials
Key Mechanisms
Desirability of outcome ranking (DOOR) framework evaluates treatment benefits and harms in the context of the trials.
Target Population
Population described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
Subgroup analysis indicated a potential benefit of omadacycline in patients with diabetes, but this finding is hypothesis-generating due to the small sample size.
Guideline-Based Recommendations
Diagnosis
Management
Consider both omadacycline and linezolid as treatment options based on patient-specific factors, as indicated in the trials.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Participants from OASIS-1 and OASIS-2 trials, totaling 1,347 patients.
Both treatments were effective, with no significant differences in outcomes.
Clinical Best Practices
Incorporate DOOR framework in future ABSSSI trials for comprehensive outcome assessment, as suggested by the authors.
